Inactive Instrument

EyeGene Inc. Share Price Other OTC

EYGN.F

KR7185490000

EyeGene Inc is a Korea-based company primarily engaged in research and development in the medical and pharmaceutical fields. The Company is mainly engaged in the research and development of messenger ribonucleic acid (mRNA)-based vaccines. The Company also develops novel treatments for ophthalmic diseases, including treatments for macular degeneration and diabetic retinopathy, as well as adeno-associated virus (AAV) gene therapy targeting rare retinal diseases. In addition, the Company develops a quadrivalent meningococcal vaccine and recombinant botulinum toxin.

Employees

Sector

Pharmaceuticals

More about the company

-40%: Exceptional extension

SEIZE THE OFFER!

Market Cap	83.43B 61.48M 53.72M 50.49M 46.08M 86.48M 5.88B 86.5M 606M 234M 3B 231M 226M 9.68B	P/E 2024	-5.71x	P/E 2025	-3.1x
Enterprise Value	38.5B 28.37M 24.79M 23.3M 21.26M 39.9M 2.71B 39.91M 280M 108M 1.38B 107M 104M 4.46B	EV / Sales 2024	11.6x	EV / Sales 2025	8.48x
Free-Float	70.86%	Yield 2024 *	-	Yield 2025	-

09-04	MVRIX Co., Ltd. announced that it has received KRW 8 billion in funding from InterVest, Korea Investment Partners Co. Ltd., EyeGene Inc., Korea Omega Investment Corp, Lifecore Partners, SNU Technical Holdings	CI
16/09/25	Eyegene Inc to conduct capital increase of 32 billion won for operational funds	RE
20/12/23	EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
12/12/23	EyeGene Inc. announced that it expects to receive KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
15/05/23	EyeGene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
15/03/23	EyeGene Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
07/04/22	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
04/10/21	Maravai LifeSciences : Says Unit TriLink To Supply Proprietary Technology to EyeGene for Production of COVID-19 Vaccine	MT
20/09/21	EyeGene Inc.(KOSDAQ:A185490) added to S&P Global BMI Index	CI
17/09/20	EyeGene Inc. announced that it has received KRW 22 billion in funding from a group of investors	CI
15/09/20	EyeGene Inc. announced that it expects to receive KRW 22 billion in funding from a group of investors	CI
23/09/19	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
27/09/18	EyeGene Inc. announced that it has received KRW 29.9998664 billion in funding from Meritz Securities Co., Ltd., Investment Arm, IBK Capital Corporation, Korea Investment & Securities Co., Ltd., Investment Arm	CI

Manager	Title	Age	Since
Suk-Keun Choi CEO	Chief Executive Officer	59	19/02/2024
Myeong-Jae Lee DFI	Director of Finance/CFO	57	30/04/2012
Won-Il Yoo PSD	President	63	22/06/2000

Director	Title	Age	Since
Won-Il Yoo BRD	Director/Board Member	63	22/06/2000
Myeong-Jae Lee BRD	Director/Board Member	57	19/02/2024
Dal-Hyun Kim BRD	Director/Board Member	64	12/05/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EYEGENE INC.	-.--%	-.--%	-	-	61.79M
ELI LILLY AND COMPANY	+0.45%	+3.00%	+55.00%	+112.54%	1,038B
JOHNSON & JOHNSON	-0.10%	+0.74%	+54.52%	+67.72%	649B
ABBVIE INC.	+0.28%	+0.82%	+19.15%	+73.63%	467B
ROCHE HOLDING AG	-0.19%	+0.97%	+34.30%	+45.99%	355B
NOVARTIS AG	+0.28%	+2.30%	+18.47%	+26.67%	269B
ASTRAZENECA PLC	+0.89%	+4.59%	+10.19%	+14.72%	260B
AMGEN INC.	+4.34%	+9.21%	+43.44%	+53.25%	213B
NOVO NORDISK A/S	-0.46%	-6.20%	-32.46%	-59.65%	176B
GILEAD SCIENCES, INC.	+1.40%	+4.35%	+35.72%	+103.53%	187B
Average	+0.65%	+2.04%	+26.48%	+48.71%	401.68B
Weighted average by Cap.	+0.48%	+2.08%	+36.36%	+67.14%

EyeGene Inc. Share Price Other OTC

Stocks

EYGN.F

KR7185490000

Pharmaceuticals

Valuation: EyeGene Inc.

Latest news: EyeGene Inc.

Managers and Directors: EyeGene Inc.

Other Pharmaceuticals

Financials

Company Profile

	2024	2025
Net sales	3.36B 2.47M 2.16M 2.03M 1.85M 3.48M 236M 3.48M 24.37M 9.41M 121M 9.29M 9.08M 389M	3.57B 2.63M 2.3M 2.16M 1.97M 3.7M 251M 3.7M 25.91M 10M 128M 9.87M 9.65M 414M
Net income	-12.13B -8.94M -7.81M -7.34M -6.7M -12.57M -854M -12.57M -88.09M -33.99M -436M -33.56M -32.82M -1.41B	-15.71B -11.57M -10.11M -9.51M -8.67M -16.28M -1.11B -16.28M -114M -44.02M -565M -43.46M -42.51M -1.82B
Net Debt	-30.11B -22.18M -19.39M -18.22M -16.63M -31.21M -2.12B -31.21M -219M -84.38M -1.08B -83.31M -81.48M -3.49B	-44.94B -33.11M -28.93M -27.19M -24.82M -46.58M -3.17B -46.59M -326M -126M -1.62B -124M -122M -5.21B